KDx Diagnostics Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Employees
  • 10

Employees

  • Latest Deal Type
  • Accelerator/​Inc

  • Investors
  • 1

KDx Diagnostics General Information

Description

Developer of diagnostic test devices designed to improve the early detection and management of cancer. The company offers an immunohistochemical proprietary test that detects bladder cancer from urine samples based on a novel biomarker, keratin seventeen, and is compatible with most autostainer platforms that are available in most reference laboratories, enabling clinicians to detect recurrent bladder cancers.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 14527 South Bascom Avenue
  • Los Gatos, CA 95032
  • United States
+1 (408)
Primary Industry
Diagnostic Equipment
Other Industries
Other Healthcare Technology Systems
Vertical(s)
Corporate Office
  • 14527 South Bascom Avenue
  • Los Gatos, CA 95032
  • United States
+1 (408)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

KDx Diagnostics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Accelerator/Incubator 01-Jan-2025 Completed Generating Revenue
1. Seed Round 30-May-2019 Completed Generating Revenue
To view KDx Diagnostics’s complete valuation and funding history, request access »

KDx Diagnostics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Seed-D
Seed-C
Seed-B 613,941 $0.000100 $0.75 $0.75 1x $0.75 8.11%
To view KDx Diagnostics’s complete cap table history, request access »

KDx Diagnostics Patents

KDx Diagnostics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3070222-A1 Keratin 17 as a biomarker for bladder cancer Pending 05-Aug-2016
EP-3493819-A1 Keratin 17 as a biomarker for bladder cancer Active 05-Aug-2016
EP-3493819-A4 Keratin 17 as a biomarker for bladder cancer Active 05-Aug-2016
EP-3493819-B1 Keratin 17 as a biomarker for bladder cancer Active 05-Aug-2016
EP-4115891-A1 Keratin 17 as a biomarker for bladder cancer Pending 05-Aug-2016 C12Q1/6886
To view KDx Diagnostics’s complete patent history, request access »

KDx Diagnostics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

KDx Diagnostics Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds
Saudi Biotechnology Accelerator Accelerator/Incubator
To view KDx Diagnostics’s complete investors history, request access »

KDx Diagnostics FAQs

  • When was KDx Diagnostics founded?

    KDx Diagnostics was founded in 2017.

  • Where is KDx Diagnostics headquartered?

    KDx Diagnostics is headquartered in Los Gatos, CA.

  • What is the size of KDx Diagnostics?

    KDx Diagnostics has 10 total employees.

  • What industry is KDx Diagnostics in?

    KDx Diagnostics’s primary industry is Diagnostic Equipment.

  • Is KDx Diagnostics a private or public company?

    KDx Diagnostics is a Private company.

  • What is KDx Diagnostics’s current revenue?

    The current revenue for KDx Diagnostics is .

  • How much funding has KDx Diagnostics raised over time?

    KDx Diagnostics has raised $1.66M.

  • Who are KDx Diagnostics’s investors?

    Saudi Biotechnology Accelerator has invested in KDx Diagnostics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process